Latest news

Dyax Corp. and Debiopharm S.A. report successful results of phase IIA clinical trial with DX-890 for cystic fibrosis

Debiopharm S.A. inaugurates a new State-of-the-Art Galenic Unit in Gland, Switzerland

H3 Pharma announces promising developments for the treatment of Alzheimer´s disease

Debiopharm S.A. reports study revealing that EPI-HNE4 offers protection against acute lung injury

Debiopharm SA a acquis un nouveau bâtiment à Lausanne et projette de déménager vers la fin 2004

H3 Pharma Licenses in Phase II Product for Stomach Cancer and Acquires Stake in a Human mAb Discovery Company Specializing…

Swiss company Debio R.P. announces Agreement with Inhale subsidiary Shearwater Corporation

Swiss drug developer Debiopharm announces FDA approval of Trelstar TM LA for therapeutic use

New pharmaceutical development company in Quebec : The SGF and the Swiss Group Debio create H3 BioDé